Fin Cascade
Get Android appGet iOS app

Prices as of 9 Oct 2026 close · Not investment advice

Akums Drugs and Pharmaceuticals Limited

NSE: AKUMSPharmaceuticals

Share price

₹751.85

-4.43% close of 9 Oct 2026

Market cap ₹11,654 CrP/E 38.2

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 7 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

61

out of 100 · worked out 9 Oct 2026

How the business score works

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹11,654 Cr

P/E ratio

38.2

P/B ratio

3.6

ROCE

14.9%

ROE

8.5%

Dividend yield

0.1%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹823.3052-week low ₹414.05

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 9.2% over the past year, and 2.9% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 8.6% to 12.5% over the last two years.

Whether it grew faster than its sector

It grew 2.9% a year against a sector median of 13.1% — 10.2 percentage points slower.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

Priced at 1.3 times its growth rate, on earnings growth of 29%.

Profit growthPrice per ₹1 profitPer 1% growth
Akums Drugs and Pharmaceuticals Limited — this one29%/yr38.2×₹1.3
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.1×₹6.4
Torrent Pharmaceuticals22%/yr79.4×₹3.6
Zydus Lifesciences32%/yr23.2×₹0.72
Laurus Labs Limited4%/yr100.5×₹25.1

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 64 of 130 on returns, 109 of 127 on growth, 91 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A narrow advantage: it earns 14.9% on capital, ahead of 51% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹2353 crore of cash from the business and spent ₹1316 crore on plant and equipment, with ₹1037 crore to spare; it still raised ₹360 crore from shareholders — borrowings did not rise. And the profit is real: of every 100 rupees it reported over 9 years, about 372 arrived as cash — well above the profit, more than depreciation and interest account for, so do not count on it repeating. Its cash comes back more slowly than it used to: it went from being waiting 49 days for its cash to waiting 66 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

10 of 10 checks clear · 100%

How the profit check works

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue rose 14% and profit rose 55%, while management kept full-year profit-margin guidance at 14% to 15%.

Announced 8 Aug 2026 · Consolidated · Unaudited

Revenue

₹1,167 Cr

Revenue vs last year

+13.9%

Revenue vs last quarter

+0.7%

Net profit

₹101 Cr

Profit vs last year

+55.4%

Profit vs last quarter

+24.7%

Net margin

8.7%

EPS

₹6.53

Earnings call transcript · 10 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹11,654 Cr
Prev close
₹751.85
52w High
₹839
52w Low
₹409
Enterprise value
₹10,130 Cr
Beta
1.2
Price CAGR 1y
87.0%
Price CAGR 3y
—
Price CAGR 5y
—
Price CAGR 10y
—

Ratios

Return on assets
4.7%
PEG ratio
1.3
P/E ratio
38.2
P/B ratio
3.6
EV / EBITDA
17.8
Industry P/E
37.6
ROCE
14.9%
ROCE 5y average
7.8%
ROE
8.5%
Debt / Equity
0.0
Interest coverage
5.1
Dividend yield
0.1%
ROE 3y average
10.0%
ROE last year
8.0%

Annual P&L

Annual revenue
₹4,359 Cr
Annual profit
₹256 Cr
Operating margin
12.0%
Net profit margin
5.9%
EBITDA margin
12.0%
Sales growth 3y
6.0%
Sales growth 5y
9.9%
Profit growth 3y
29.0%
Profit growth 5y
16.0%
EPS
₹16.2
Sales growth TTM
9.0%
Profit growth TTM
-7.0%
Dividend payout
18.0%

Quarter P&L

Sales latest quarter
₹1,167 Cr
Profit latest quarter
₹101 Cr
YoY quarterly sales growth
13.9%
YoY quarterly profit growth
55.4%
OPM latest quarter
15.0%

Balance Sheet

Book Value
₹214
Face Value
₹2.0
Total debt
₹157 Cr
Total cash
₹1,681 Cr
Borrowings
₹157 Cr
Reserves / Equity
105.9

Cash Flow

Operating cash flow
₹1,181 Cr
Free cash flow
₹958 Cr
FCF yield
7.4%
Net cash flow
₹285 Cr

Shareholding

Promoter holding
75.3%
FII holding
1.9%
DII holding
13.4%
Public holding
6.7%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.94,28,0570.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.52,54,6650.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.31,79,1640.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,14,9630.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.31,10,6990.10362.1125.52,026.329.117.8
Cipla1,327.2029.91,06,9970.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.71,03,8760.04574.129.64,030.612.913.5
Akums Drugs822.5542.412,9460.12101.057.51,166.613.914.9
Median417.9034.42,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales9701,1811,0839441,0191,0331,0101,0561,0241,0181,1601,1581,167
Expenses1,0951,0299899418919128899628959231,0131,006992
Material Cost548553611587682
Change in Inventories13-177.0411-63
Purchases of Stock-in-Trade2157606326
Employee Cost176189189199201
Other Expenses137141145147145
Operating Profit-1251529331281211219412994147152175
OPM %-13138.630.321312128.90139.28131315
Other Income8-21101071719262732163430
Exceptional items (within Other Income)00-18-1.800
Interest121412121312552323242425
Depreciation30303234343545403738404041
Profit before tax-1598759-33879291759666100121139
Tax %1862-22920302727-993235323327
Net Profit-18733195-3961676615065436881101
EPS in Rs-132.2214-2.894.084.144.149.384.032.594.215.386.35
Diluted EPS in Rs4.152.664.335.536.53

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,4641,6512,4142,7233,6723,6554,1784,1184,3594,502
Expenses1,3401,5072,2402,4853,7613,3614,0553,6543,8373,934
Material Cost2,299
Change in Inventories14
Purchases of Stock-in-Trade201
Employee Cost754
Other Expenses570
Operating Profit124144174238-89294123465522568
OPM %8979-2.4083111213
Other Income662611715869108112
Exceptional items (within Other Income)-20
Interest2322207174651359496
Depreciation3138677095113126153155159
Profit before tax7789114172-193150-45345382426
Tax %515062283035-102033
Net Profit436144123-251981344256293
EPS in Rs367523336943-356.63-0.28211619
Diluted EPS in Rs17
Dividend Payout %0000000018

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
10%
5 years
10%
3 years
6%
TTM
9%

Compounded profit growth

10 years
16%
5 years
16%
3 years
29%
TTM
-7%

Stock price CAGR

10 years
—
5 years
—
3 years
—
1 year
87%

Return on equity

10 years
—
5 years
6%
3 years
10%
Last year
8%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital11111429293131
Reserves4936287218846086896813,0163,283
Borrowings25521317513039561956588157
Other Liabilities2933181,1401,1372,0331,9052,2299601,958
Minority Interest18
Total Liabilities1,0421,1612,0372,1523,0503,2413,5044,0955,429
Fixed Assets4445016459041,0211,0971,1911,3971,456
CWIP011571731103195163177
Investments01862000000
Other Assets5986321,3291,2121,9982,0412,1182,5353,796
Total Assets1,0421,1612,0372,1523,0503,2413,5044,1135,447

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity728928131321774984651,181
Cash from Investing Activity-150-123-190-109-235-305-331-548-930
Cash from Financing Activity6637233-91236125-1087334
Net Cash Flow-11471-7033-459-10285
Free Cash Flow-78-34-3449-224-110212201958

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days685788718884736867
Inventory Days114115999311211790102110
Days Payable6760105749291769687
Cash Conversion Cycle1151128290109111877489
Working Capital Days787355664946407166
ROCE %1420-162221615

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters7575757575757575
FIIs7.346.365.774.242.271.141.381.91
DIIs7.536.997.398.859.28141413
Public7.148.648.848.92106.456.296.67
Others2.732.732.732.732.732.732.732.73
No. of Shareholders57,53168,41069,36669,42475,36576,86972,58970,289

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +68.5% (₹446.15 → ₹751.85)Brick size ₹30.09 (fixed)Bricks 13
₹600₹800₹752Feb '26Jul '26
Price moved up one brickPrice moved down one brickLast close ₹751.85 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

company capacity utilisation %

50.00pct

2026-06-30

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-1,524inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

59,41,120inr

2026-03-31

volume growth %

20.00pct

2025-12-31

News

News and filings about Akums Drugs and Pharmaceuticals Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Active pharmaceutical ingredients (APIs)
  • Excipients
  • Key starting materials (KSMs) and intermediates
  • Packaging materials
  • Solvents

Sells to

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE09XN01023

Business segments

  • CDMO · 80%
  • Domestic Branded Formulations · 10%
  • API · 4%
  • International Branded Formulations · 3%
  • Trade Generics · 2%

Plants

  • Akums Baddi facility
  • Akums Haridwar API facilities
  • Akums Haridwar formulation facilities

News impact

Big market events that reach Akums Drugs and Pharmaceuticals Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

3 Jul 2026unspecified₹1
3 Jul 2026special₹2

Splits, bonuses & buybacks

  • daily-prices repair: 1 rows from NSE's archive (replace 0, delete 0, insert 1), 2026-02-01..2026-02-01 (docs/flat_day_repair.md)1× · 1 Feb 2026

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.